Skip to main content
. 2011 Jul 6;6(7):e21611. doi: 10.1371/journal.pone.0021611

Figure 2. Ceacam1 regulates GVHD target organ damage.

Figure 2

A) 5×106 TCD-BM ± 1×106 T→BALB/c. Day 21. Histopathology score. N = 5–12/group. SB, small bowel. LB, large bowel. B) Thymocyte count and apoptotic skin cells from (A). N≥7/group. Day 21. One of two representative experiments. C) Apoptotic skin cells from (A). N≥7/group. Day 21. D) 5×106 TCD-BM ± 1×106 T→BALB/c. Histopathology score. Day 21. N≥7/group. SB, small bowel. LB, large bowel. E) Thymocyte counts from (E): N≥7/group. One of two independent experiments. DP: CD4+CD8+ double-positive thymocytes. Day 21. F) Apoptotic skin cells from (E). N≥7/group. Day 21. G) 5×106 TCD-BM ± 1×106 T→WT or Ceacam1−/− BALB/c. Histopathology score. Day 14. N≥12/group. SB, small bowel. LB, large bowel. H) Thymocyte count from (I). N≥8/group. One of two independent experiments. DP: CD4+CD8+ double-positive thymocytes. Day 14.